Although we enrolled a significant number of ALS patients, the well-known high variability of the disease did not allow us to draw definitive conclusions about the effect of ALS clinical variants, FTD status, and ALS gene mutations on plasma and CSF NfL levels. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.